Impact of Periprocedural and Technical Factors and Patient Characteristics on Revascularization and Outcome in the DAWN Trial.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
01 2020
Historique:
pubmed: 21 11 2019
medline: 15 4 2020
entrez: 21 11 2019
Statut: ppublish

Résumé

Background and Purpose- Because of unique attributes of mechanical thrombectomy performed between 6 and 24 hours after symptom onset in acute ischemic stroke patients, it is not known if predictors of angiographic recanalization and favorable outcome in patients treated with thrombectomy in the late (6-24 hour) time window are similar to those treated in the early time window. Methods- We analyzed data from the DAWN trial (DWI or CTP Assessment With Clinical Mismatch in the Triage of Wake-Up and Late Presenting Strokes Undergoing Neurointervention With Trevo) which enrolled patients with symptom onset 6 to 24hours after last known well and occlusion of the intracranial internal carotid artery or proximal middle cerebral artery with a mismatch between severity of clinical deficit and infarct core volume as identified by computed tomography-perfusion or diffusion magnetic resonance imaging. We evaluated the effect of tandem occlusions, periprocedural heparin use, procedural speed (from puncture to procedure completion), general anesthesia, balloon-guide catheters, thrombectomy device size, and number of passes on substantial reperfusion (modified Thrombolysis in Cerebral Infarction 2b/3) and on likelihood of obtaining a modified Rankin Scale at 3 months indicating functional independence. Results- Of 107 patients who underwent MT in the interventional arm of DAWN, substantial reperfusion and modified Rankin Scale score 0 to 2 at 3 months was seen in 90 (84%) and 52 (49%), respectively. In univariate analysis, general anesthesia (odds ratio [OR] 0.27;

Identifiants

pubmed: 31744425
doi: 10.1161/STROKEAHA.119.026437
doi:

Substances chimiques

Heparin 9005-49-6

Banques de données

ClinicalTrials.gov
['NCT02142283']

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

247-253

Auteurs

Wondwossen G Tekle (WG)

From the Valley Baptist Medical Center, Harlingen, TX (W.G.T., A.E.H.).

Ameer E Hassan (AE)

From the Valley Baptist Medical Center, Harlingen, TX (W.G.T., A.E.H.).

Ashutosh P Jadhav (AP)

The Stroke Institute, Department of Neurology, University of Pittsburgh Medical Center, PA (A.P.J.).

Diogo C Haussen (DC)

Emory University School of Medicine/Grady Memorial Hospital, Atlanta, GA (D.C.H., R.G.N.).

Ronald F Budzik (RF)

Riverside Methodist Hospital, Columbus, OH (R.F.B.).

Alain Bonafe (A)

Department of Neuroradiology, Hôpital Gui de Chauliac, Montpellier, France (A.B.).

Parita Bhuva (P)

Division of Neurointervention, Texas Stroke Institute, Dallas-Fort Worth (P.B.).

Dileep R Yavagal (DR)

University of Miami Miller School of Medicine-Jackson Memorial Hospital, FL (D.R.Y.).

Ricardo A Hanel (RA)

Lyerly Neurosurgery, Jacksonville, FL (R.A.H.).

Marc Ribo (M)

Stroke Unit, Hospital Vall d'Hebron, Barcelona, Spain (M.R.).

Christophe Cognard (C)

Department of Diagnostic and Therapeutic Neuroradiology, University Hospital of Toulouse, France (C.C.).

Cathy A Sila (CA)

University Hospitals-Cleveland Medical Center, OH (C.A.S.).

Wade S Smith (WS)

Department of Neurology, University of California, San Francisco, (W.S.S.).

Jeffrey L Saver (JL)

Department of Neurology and Comprehensive Stroke Center, David Geffen School of Medicine, University of California, Los Angeles (UCLA) (J.L.S., D.S.L.).

David S Liebeskind (DS)

Department of Neurology and Comprehensive Stroke Center, David Geffen School of Medicine, University of California, Los Angeles (UCLA) (J.L.S., D.S.L.).

Ryan Shields (R)

Stryker Neurovascular, Fremont, CA (R.S.).

Raul G Nogueira (RG)

Emory University School of Medicine/Grady Memorial Hospital, Atlanta, GA (D.C.H., R.G.N.).

Tudor G Jovin (TG)

Cooper University Hospital, Neurological Institute, Camden, NJ (T.G.J.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH